Your prediction
Pros and Cons of Merrimack Pharmaceuticals Inc. in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Merrimack Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Merrimack Pharmaceuticals Inc. | - | - | - | - | - | - | - |
| Ardelyx Inc. | 5.570% | 2.840% | 1.187% | 5.509% | 6.465% | 176.349% | -3.856% |
| Krystal Biotech | 0.330% | 3.678% | 18.962% | 25.776% | 37.057% | 193.803% | - |
| Evolus Inc | -4.200% | -1.724% | -8.065% | -47.706% | -45.714% | -18.571% | 88.742% |
Comments
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Show more
Ratings data for MACK provided by MarketBeat
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Show more
Ratings data for MACK provided by MarketBeat
